Black Diamond Therapeutics, Inc. Share Price & Technical Analysis
BDTX · $2.28 (-35.77%)
Healthcare / Biotechnology
$2.28
-35.77%
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-15% return in May, 17% avg return in past 3 year May month.
0% return in 2026, 69% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | 0% | -12% | 23% | -15% | – | – | – | – | – | – | – | 0% |
| 25 | 18% | -20% | -25% | 13% | 29% | 14% | 8% | 8% | 41% | 0% | -3% | -37% | 47% |
| 24 | 36% | 31% | -2% | 10% | -13% | -4% | 30% | 0% | -28% | -37% | -4% | -19% | -1% |
| 23 | 58% | -40% | 6% | -26% | 36% | 168% | -24% | -8% | -15% | -34% | 21% | 22% | 162% |
| 22 | -21% | -26% | -10% | -11% | -29% | 47% | 40% | -9% | -47% | 28% | -12% | -14% | -64% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$158.22M
P/E ratio
—
52W high
$4.94
52W low
$1.93
Volume
83,82,098
Beta
3.35
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Black Diamond Therapeutics, Inc. share price today?
- Black Diamond Therapeutics, Inc. (BDTX) last traded around $2.28 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BDTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BDTX. Download the app for real-time alerts.
- How can I analyze Black Diamond Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.